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INTRODUCTION 
 
  
SUSPENSION  
  It may be defined as a coarse dispersion of finely subdivided insoluble 
solid drug suspended in a suitable liquid (usually aqueous) medium.1 
  It is a heterogeneous system consisting of a solid disperses in a solid, 
liquid or gas.2 
  It is a biphasic preparations particle of one or more solids basically it 
may be flocculated or deflocculated.3 
ORAL SUSPENSION    
  It contains one or more active ingredients suspended in a suitable 
vehicle.Suspended solids may slowly separate on keeping but are easily redispersed.  
It should be packed in wide mouth bottles.4 
 
ADVANTAGES OF ORAL SUSPENSIONS 
 It is a better means of administration than of solid dosage forms such as tablet, 
capsules especially when swallowing is difficult.1 
1. It is an ideal dosage form for infants and old patients because of easy 
administration.5  
2. It contains sub-divided solid particles, surface area is large and this is 
taken advantage of drugs which are adsorptive.1 
3. Suspensions are chemically more stable than solutions.5 
DESIRABLE PROPERTIES OF SUSPENSIONS 1 
1. It should not be rapid settling of suspended particles. 
2. The particles do settle they must not form a hard cake at the bottom of the 
container. 
3.  It should be redispersible into uniform mixture when shaken. 
4. A suspension should be easily pourable. 
5. The colour and odour should be acceptable and pleasing for oral and external 
uses. 
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6. Appropriate preservatives should be incorporated in order to minimize the 
microbial contamination.5 
 
PROBLEMS OF SUSPENSIONS 4 
1. Wetting of disperse phase. 
2. Settling of disperse phase and resuspendibility of settled matter. 
3. Particle – particle interactions leads to particle size growth or caking. 
To formulate a suspension the above problems have to be overcome. 
 
FORMULATION OF SUSPENSIONS 4 
 In designing a suspension formula, a number of factors must be kept in sight. 
First of all a decision has to be taken whether a flocculated or non-flocculated 
system has to be evolved. Secondly, it’s important to ensure that the disperse phase 
particles are well dispersing in the continuous phase. Then finally the decision have 
to be taken about suspending agents, dispersants, organoleptic additives and 
preservatives is required to produce satisfactory suspension. 
 The choice of an appropriate suspending agent depends upon the use of 
products, facilities for preparation and the duration of product storage. 
 
PHARMACEUTICAL APPLICATIONS OF SUSPENSION 1 
1. FOR ORAL USE  
 A suspension provides convenient means of administering an insoluble drugs 
as compare to tablets or capsules as far as swallowing is concerned. 
 Suspensions are fast acting because of more surface area. Eg. CaCO3   
 Insoluble derivatives of drugs are often used to reduce the unpleasant taste.   
Eg . Chloramphenicol palmitate 
 Insoluble drugs which are susceptible to hydrolysis are dispensed as dry 
syrups and are reconstituted with water at the time of use.  Eg. Ampicillin 
Dry syrup 
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B)     FOR EXTERNAL USE                                                                                            
 A number of lotions are of suspension type. Eg.Calamine lotion 
 Semisolid Suspensions are paste. Eg. Tooth paste  
C) FOR INJECTIONS  
 Insoluble drugs which are susceptible to hydrolysis are dispersed as sterile 
powders in vials. At the time of their use they are reconstituted with sterile 
water injection. Eg. Penicillin injection. 
 
EVALUATION OF SUSPENSIONS 4 
  A number of procedures have been suggested in the past for evaluating 
the physical stability of suspensions.  Some of these are empirical in the sense that 
they have no mathematical base.  Some methods currently being used are so drastic 
that they destroy the structure of suspension.  The methods used may be categorized 
as 
 Sedimentation methods 
 Rheological methods 
 Electro kinetic methods 
 Micrometric methods 
 
TASTE MASKING 
  Swallowing tablet is a problem for many patients particularly for 
children and geriatric patients because of when the tablets are large. So prefer oral 
dosage form.  Certain medicaments have an unpleasant taste in the throat when they 
after orally administered. So some agents are disclosed which when incorporated in 
the composition mask these bitter taste.6 
  The conventional oral dosage forms possess sustained release anti – 
tussive characteristics. 
  Microcapsules are formulated into chewable taste masked oral tablets  
or capsules the formulation provide for immediate rapid release in the stomach. The 
meth acrylic acid copolymer can be a copolymer of polymethacrylic acid and acrylic 
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acid esters. These polymers coating should be used for immediate release 
characteristics in microcapsule techniques.7  
  Many drugs containing amine or amide groups or salts there of often 
have a strong bitter taste. Taste masking techniques using various sweeteners, amino 
acids, flavours & adsorbents have been unsuccessful in masking the taste. In most 
coating techniques don’t have an acceptable in-vivo drug releasing mechanism. 
Cat ion exchange resins have been used to adsorb amine drugs for sustained release 
action & taste masking .The widely used cat ion – exchange resins are poly sulfonic 
acid & poly carboxylic acid polymers3. 
  A variety of delivery systems are being developed for different routes 
of administrations like oral, parenteral, nasal & transdermal, The oral route remain 
attractive for drug delivery because this mode of administration is an easy, 
convenient, noninvasive & familiar method of drug delivery oral dosage forms are 
designed according to the nature of the drug.8 
  The common oral dosage forms include liquid mixtures like tablets, 
capsules & liquid filled capsules. The solid dosage forms are further modified 
depending on the therapeutic action desired like controlled, extended, or delayed 
release.  
  Patients at the extremes of age, such as children and the elderly often 
experienced difficulty in swallowing solid dosage forms such as solutions, 
emulsions & suspensions. These dosage forms usually lead to perceptible exposure  
of the active drug ingredient to the taste buds, which is a very serious problem when 
the drag has an extremely unpleasant.9 
  Conventional taste masking techniques such as sweeteners, amino 
acids, flavoring agents are often unsuccessful in masking the taste of the highly 
bitter drugs like quinine, barberin, antibiotics like ofloxacin & clarithromycin. 
  Taste masking is a major problem when the drugs are extremely 
unpleasant this problem is not restricted to the liquid oral composition like solutions, 
dry syrup & suspensions but may also be encountered during the formulation of 
chewable tablets where in these dosage forms usually lead to perceptible exposure 
of active ingredient to taste buds. Depending on the type of dosage form various 
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methods have been employed to overcome the unpleasant taste and bitterness of the 
drug.  
  Various method for taste masking have been tried earlier which 
include use of  ion exchange resins, complexation of bitter drugs with 
pharmaceutically acceptable recipients and coating of drugs by lipids using a various 
polymeric materials. The coating is the most widely used technique for taste 
masking. Coating of the active ingredient can be done by any of the techniques 
known in the art like microencapsulation. 
  The use of ion exchange resins to absorb drugs containing amino 
groups for taste masking has found limited applicability in masking the taste of 
highly bitter drugs, and also where the drugs is to be dispersed in a liquid oral 
composition for long duration of time. 
  Another technique is mouth disintegrating tablet. In this method, 
disintegrate in oral cavity with saliva in 15 sec to 60 sec, without need of water and 
should have pleasant mouth feel.10 
                    The two methods were followed for the formulation of mouth 
disintegrating tablets. 
 By addition of sweeteners and disintegrants. 
 Mass extrusion technique. 
  These taste masking formulations frequently are flavoured such as 
with fruit or mint flavours, usually for purposes of masking an unpleasant taste 
caused by the presence of a dissolved or suspended pharmacologically active 
substance. A pleasant taste is particularly important when the formulation is 
intended for ingestion by children. The  typical flavours which are commonly used 
in formulations. The important flavours such as grape, cirus, peach, strawberry, 
peppermint and many other  flavors. 
  In these formulations, non- sugar based artificial sweetening agents 
like sucralose & saccharin are used. 
  Typically suitable pharmaceutically acceptable solvents and or carriers 
systems include water, alcohols & glycerin are used.11 
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  Suitable buffering systems are also used in the formulations. That is 
citric acid & phosphoric acid buffer systems. The citric acid buffer system 
preferably contains sodium citrate in combination with citric acid. 
  In these formulations, PH range is about 4.5 to 6.5 preferably 5.5 is 
maintained. 
  Suitable thickening agents are used in these taste masking 
formulations that is xanthangum, guargum, gelatin, taragum, tracaganth gum and 
many others.12 
  In this taste masking formulations, to prevent microbial contamination, 
preservatives like sodium benzoate (0.1 to 0.2%) or benzoic acid is used. 
  Stabilizers also be incorporated into the taste masking formulations in 
the amounts of about 0.01 to 5% preferably about 0.25%.  
 
TECHNIQUES EMPLOYED FOR TASTE MASKING  
 
   The methods commonly employed for achieving effective taste 
masking include various physical and chemical methods that prevent the drug 
substance from interaction with the taste buds.     
 
A) Use of Flavor Enhancers 
                          
                        The materials for taste masking purpose have often been classified 
depending upon the basic taste that is masked.13 Flavoring and perfuming agents can 
be obtained from either natural or synthetic sources. Natural products include fruit 
juices, synthetic products like aromatic oils such as peppermint oil and lemon oil, 
herbs, spices and distilled fractions. They are available as concentrated extracts, 
alcoholic or aqueous solutions, syrups or spirit.14Apart from these conventional 
materials many compositions have been found to show effective taste masking 
abilities with improved flavor such as alkaline earth oxide, alkaline earth hydroxide 
or an alkaline hydroxide.15 Another composition includes phosphorylated amino 
acid such as phosphotyrosine, phosphoserine, and phosphothreonine and mixtures 
thereof.16 Anethole effectively masked bitter taste as well as the after taste of zinc, 
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which is use in treating the common cold17. Clove oil and calcium carbonate which 
has been found to be particularly useful to mask the unpalatable active in 
formulation which are intended to be chewed or dissolve in mouth prior to ingestion 
in solution.18 
 
B) Applying Polymer Coatings 
   
  Coating of drugs  using a suitable polymer offer  an excellent method 
of concealing the drug from the taste buds. The coated composition may be 
incorporated into much number of pharmaceutical formulations, including chewable 
tablet, effervescent tablets, powder and liquid dispersion.19-21 
  Multiple encapsulated flavour delivery systems has been developed 
which is useful in chewing gum, pharmaceutical preparations as well as other food 
products.22 
 
C) Complexation and Adsorption Approaches23 
 
Complexation with ion exchange Resins and Polymers 
  
  Cat ion-exchange resin CRP 244 and anion exchange ion were used to 
adsorb ester drugs for both masking of bitter taste and achieving sustained release 
action. The types of ion exchanges resins that have been successfully used to mask 
the taste of bitter drugs include amberlite IRP 88    (an acrylic potassium  resin), 
amberlite IRP 64 (a polystyrene sulphonate) and amberlite IRP  64 (a carboxylate 
form of the methapyrilene, dextromethrophan, ephedrine and pseudoephedrine) 
were masked by first forming adsorbates with polymethacrylic acid ion exchange 
resin followed by coating of resin complex with 4:1 mixture of ethyl cellulose and 
hydroxy propyl methyl cellulose (HPMC)polymers. 
   Prepared high potency adsorbents of methapyrilene, dextromethophan, 
ephedrine, pseudoephedrine by column procedures using a polymethacrylic acid ion 
exchange resin. Taste evaluation of the adsorbents showed a significant reduction in 
the bitterness of the drugs. Coating adsorbent particles with 4:1 ethyl cellulose-
HPMC mixture reduced the bitterness further. Taste coverage was maintained after 
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incorporation of the coated adsorbent in to chewable tablets. Strong acid cat ion 
resins (sulfonated styrene divinyl benzene copolymer product) can be used for 
masking the taste of basic drugs.23 Polystyrene matrix cat ion exchange resins have 
been used to mask the bitter taste of chlorpheniramine malate, ephedrine 
hydrochloride and diphenhydramine hydrochloride.24 Extreme bitterness of 
quinolones has been achieved by ion exchange resin such as methacrylic acid 
polymer cross linked with divinylbenzene.25 
 
DRUG RESIN COMPLEXES  
 When an ionizable drug reacts with a suitable ion exchange resin, the drug-
resin complex formed is known as a drug resinate. Since the drug resinate is 
insoluble, it has virtually no taste, so that even very bitter drugs lose their taste when 
converted into a drug resinate with the correct selection of the ion exchange resin.  
The drug resinate can be made sufficiently stable that it dose not break down in the 
mouth so that the patient does not feel the taste of drug when it is swallowed. 
However, when the drug resinate come in contact with gastrointestinal fluids, 
usually the acid of the stomach. The complex is broken down quickly and 
completely. The drug is released from resinate directly into the solution and then 
absorbed in the gastrointestinal tract without being absorbed. 
 
D) Formulation of Inclusion Complex with Beta Cyclodextrin Derivatives12 
  Cyclodextrin are cyclic oligomers of glucose. They form inclusion 
complexes with any drug whose molecules can fit to the lipophile seeking cavities of 
the cyclodextrin molecule. The resulting complexes can marked improve the coating 
with suitable lipids, such as palmitic or stearic acid, glyceryl tripalmitate, glyceryl 
tristearate or a mixed acid ester triglyceride and stearyl alcohol.26,27 
 
E)  Wax Embedding of Drugs12 
  Taste masked by wax embedded granules of ephedrine hydrochloride, 
chloropheniramine maleate and Diphenhydramine hydrochloride were prepared in 
stearic acid and other waxes. 
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F)  Other Techniques 
  These include solubility-limiting methods incorporation of drugs in 
vesicles and liposome and chemical modification.28,29 The solubility limiting method 
can be applied to a number of drugs whose taste profiles are dependent on aqueous 
solubility. 
  Chemical modification such as derivatization or lipophillic counter ion 
selection may be an effective method for reducing aqueous solubility and taste. 
Erythromycin monohydrate, a bitter tasting drug with a solubility of 2 mg/ml is 
chemically converted into erythromycin ethyl succinate, the aqueous solubility is 
reduced to the <50mcg/ml.This form is tasteless and can be administrated as a 
chewable tablet.  Incorporation of drugs into Vesicles or liposomes is although an 
ideal technique. Yet a  challenge to formulate without altering the regulatory status 
of the product (in-vitro dissolution kinetics, physical or chemical stability or 
bioavailability). 28 
  Anesthetizing agent like sodium phenolate, which numb the taste buds 
sufficiently within 4-5 seconds is helpful in inhibiting the perception of the 
formulation30. Substances like lipids, carbohydrate, lecithin, gelatin and polyamines 
has been effectively used for taste masking of drugs.31 
  Another novel technique employing mulitiple emulsions has also been 
reported. By dissolving drug in the inner aqueous phase of w/o/w emulsion under 
condition of good shelf stability, the formulation is designed to release drug through 
oil phase in the presence of gastric fluid.32 
  In one of the method drugs with bitter taste are combined with non-
ionic surfactants to form composites by hydrophobic interactions resulting in taste 
masking.33 
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TECHNIQUES EMPLOYED FOR TASTE MASKING OF DIFFERENT 
DOSAGE FORMS34 
  The drug i.e. the active pharmaceutical ingredient is finally formulated 
in a suitable dosage form such as tablet, powder, liquid, etc. 
 
(i) Tablets 
  Most of the tablets can be effectively masked for their taste by 
applying inert polymer coatings that prevent the interaction of the drug substances 
with the taste buds. Nevertheless, attempts have been made time and again by 
several workers to investigate and explore the use of newer materials in bad taste 
abatement and good taste enhancement.  
 
(ii) Granules / powders 
  Granules for reconstituting as liquids (e.g. sachets, sprinkle capsules & 
powder) hold a high share of pediatric and geriatric market. A large number of 
patients on the topic highlight the significance of the same. Thus taste masking of 
granules becomes an important priority in product development and varied 
technologies and methodologies. 
 
(iii) Liquids 
  They present major challenges in taste majority of pediatric 
preparation are syrups and suspensions although, the aforementioned methodologies 
have also had been used for improving liquid taste and few patents in this area are 
worth mentioning.      
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LITERATURE REVIEW 
 
01. Akemi N et al. 35 developed a method of taste of clarithromycin using a 
spray congealing technique using glyceryl monostearate and amino alkyl  
methacrylate copolymer showed that in ratio 3:6:1 for clarithromycin  glyceryl 
monostearate and aminoalkyl methacrylate copolymer showed better result. 
02. Hiroyo S et al. 36 studied taste making of bitter drug powder of 
indelozagine hydrochloride by mixture comprising hydrogenated on and 
surfactant in fluidized bed dryer using the side spray method showed that by 
heat treatment the coated particles at a room temperature above the melting 
point of a surfactant in the coated layer cause remarkable increase in dissolution 
rate. 
03. Geeta Rao CG et al. 37 formulated taste masked oral suspension by 
complexation technique using ion-exchange resins. The suspension was 
evaluated and release studies showed complete drug release within 20 minutes 
stability studies indicated no appreciable change in suspension. 
04. Kishimoto et al. 38 used mannitol and lactose in different weight ratios         
(1:1.5-1:5) as coating materials for masking bitter taste of solid drug 
preparations. 
05. Yajima et al. 39 described in their patent with a composition comprising of 
a drug with unpleasant taste of polymer solution and D-crystals of 
monoglycerides. Eudragit-E (100g), monoglyceride (600g) and then 
erythromycin (300g) were added to the mixture to obtain a powder to give taste 
masked granules of erythromycin. 
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06. Danielson et al. 40 invented a dosage form comprising a granules 
containing the histamine receptor antagonist which are provided with taste 
masking comprising a water  insoluble, water permeable methacrylate ester 
copolymer  in which the coating is applied to the granules in an amount which 
provides a  taste masking effect for a relatively  short period during which the 
composition is being chewed by the patient but which allows substantially 
immediate release of the histamine receptor antagonist after the composition 
has been chewed and ingested. 
07. Kumar et al. 41 provided a means and method for manufacturing palatable 
drug granules using a copolymer having least one free carboxyl group and poly 
vinyl pyrolidone.  
08. Meyer et al. 42 used Prolamine as single coating in weight ratio 5% to 
100% relative to active substance being coated result in the production of liquid 
suspension which effectively masked the taste of orally administered drugs 
which are extremely bitter. Prolamine coating is effective in masking the taste 
of antibiotics, vitamins. analgesics,enzymes and hormones. 
09. Nakona et al. 43 masked the bitter taste of vitamin B1 derivatives such as 
dicethimines by formulating with methanol and or poly oxyethylene, poly oxy 
propylene for formulating oral liquids. 
10. Osugi et al. 44 subjected in their invention oral liquids containing 
Diclofenac and its salts to heat treatment in the presence of glycine, said  there 
of to mask the bitter taste and to prevent  the irritation of the throat  upon oral 
administration. 
11. Morella et al. 45 invented a liquid suspension of microcapsules taste 
masked as a function of a polymer coating and the pH of suspended medium at 
which pharmaceutically active ingredients remain substantially insoluble. 
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12. Swaminathan et al. 46 developed pharmaceutically composition 
comprising polyhydric alcohol based carrier to mask the bitter taste of drug. 
13. Yu et al. 47,48 invented a liquid composition comprising a pharmaceutically 
active medicament coated with a taste masking effective polymer blend of 
dimethylaminoethyl methacrylate and natural methacrylic acid aster and a 
cellulose ester in an aqueous vehicle. 
14. Cuna et al. 49 prepared micro encapsules of cefuroxime axetil with various 
cellulosic polymers having a pH dependent solubility; CAT, BPMCP-55 and 
UPMCP-50, with the final aim to mask its taste while assuring its release in the 
intestinal cavity. 
15. Kato et al. 50 studied the low melting point  substances for masking bitter  
taste of the drug beef tallow was mixed with micropulverized active ingredients 
and the mixture was nozzle sprayed to form coated spheres having homogenous 
particle size. 
16. Maccari et al. 51 conducted a special study to assess the bioavailability of a 
Flucoxacillin preparation microencapsulated for taste abatement with 17 %   
ethyl cellulose made up as a granular product for extemporaneous resuspension 
when compared to commercially available flucoxacillin preparations. 
17. Udea et al. 52 described a novel microencpsulation process combined with 
the wet spherical agglomeration technique by using modified phase separation 
method in order to mask the bitter taste of drug. 
18. Yekta Ozer et al. 53 mictoencapsulated Beclamide in order to mask the 
bitter taste by a simple co-acervation method using-gelatin. 
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19. Borodkin et al. 54 prepared high potency adsorbates of Methapyrilene, 
Dextromethorphan, Ephedrine, Pseudoephedrine by column procedures using a 
polymethacrylic acid ion exchange resin. 
20. Yoshimi et al. 55 studied the influence of heat treatment on dissolutions and 
masking degree of bitter taste for novel fine granule system. 
21. Cuna M et al. 56 disclosed microeneapsulation of highly bitter drug 
Cefurorxime Axetil for taste masking by using different polymeric materials 
like cellulose acetate trimellitate, HPMC-50, HPMCP-55 with the final aim to 
mask the taste and assuring its release in the intestinal cavity. 
22. Alonso et al. 57 developed the encapsulation of Cefuroxime Axetil, a highly 
bitter drug, in pH sensitive acrylic microspheres in order to formulate a 
suspension dosage form is described. The acrylic polymers used were Eudragit- 
E, Eudragit RL – l00, Eudragit L-100, 55. The cationic polymer Eudragit-E 
showed a negative interaction with cefuroxime axetil. The enteric polymer 
Eudragit L-100 and 55 showed a favourable release  in alkaline pH. 
23. Dantzig et al.58 showed the cefuroxime axetil is hydrolyzed to cefuroxime 
in the intestinal lumen by the esterases reducing the cefuroxine axetil 
concentration in the lumen and resulting in reduced absorption leading to low 
bioavailability of cefurokime axetil in humans. Cefuroxime axetil already has a 
low bioavailablability of 32-50% and hence further reduction in the 
bioavailability due to the formulation aspects should be minimized. 
24. Patent Application WO 00/56266 59 disclosed the use of high viscosity 
swellable polymer carbomer in combination with film forming 
polymethacrylates and channelising agents for taste masking of bitter drugs. 
The addition of the water swellable polymer aids in the fast release of the active 
ingredient in the gastric media. 
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25. Patent Application 100 00/76479 60 disclosed a taste masking 
composition, using a combination of two enteric polymers comprising a 
methacrylic acid copolymer comprising a methacrylic acid copolymer and a 
phthalate polymers is disclosed. The enteric polymers as disclosed  in the patent 
are known to release the active ingredient in the alkaline pH where the 
polymers are soluble. 
26. British Patent 2081092 61 disclosed a lipid coating for the purpose of taste 
masking. It was however found that wax coating resulted in poor dissolution of 
the active ingredients in the alimentary tract. Further the patent discloses a 
technique to over come this problem by mixing the waxes with a water 
swellable polymer. The use of water swellable polymer referred to in the patent 
makes it less appropriate for the liquid orals like suspension and dry syrup. 
27. US Patent No. 5,286,489 62 described a porous drug polymer matrix 
formed  by admixing a bitter tasting active ingredient and a methacrylic ester 
copolymer in at least a 1:1  weight ratio of active ingredient to copolymer, 
effective  to mask the taste of the drug. 
28. Patent Applications WO 02/072111 63 disclosed a taste masked 
pharmaceutical suspension of telithromycin. For different coating agents 
Novata-AB, Eudragit E-100, glycerol monostearate and talc M 10 are employed 
and at least three successive layers of coating are essential to taste mask 
telithromycin. The coated grranules as disclosed could further be formulated as 
dry syrup, which is reconstituted as a suspension. 
29. US Patent.No.4,865,851 64 disclosed for taste masking highly bitter 
lacetoxy ethyl ester of Cefuroxime in particular form being coated with an 
integral coating of lipid or a mixture of lipids, which  serves to mask the bitter 
taste. 
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30. US Patent Application 2003-02802565 disclosed taste masked composition 
of gatifloxacin suitable for use in oral dosage forms, particularly for pediatric 
formulations. A crystalline co-precipitate of gatifloxain and one or both of 
stearic acid and palmitic acid is used to effectively mask the bitter taste of 
gatifloxacin in the mouth and in a aqueous suspension through a full dosage 
cycle of fourteen days. 
31. US Patent No.5,635, 20066 disclosed a taste  masked preparation of bitter 
drug ranitidine by a lipid coating and dispersion of these  coated particles  in the 
non-aqueous medium. 
32. US Patent No.4808, 41167 disclosed a taste masked composition 
comprising 75-95% of erythromycin and about 5 to 75% of carbomer where the 
drug and carbomer are held together by ionic interactions between 
erythromycin and carbomer. The complex is further coated with a functional 
polymer, HPMC, phthalate to mask the preparation palatable complexing alone 
is not sufficient enough to mask taste. Coating with functions polymers is 
required to attain desired palatability. 
33. US Patent 651449268 disclosed the use of exchange resin AMBERLITE. 
RTM. IRP 69 for taste masking of quinolone derivatives there by eliminating 
the extreme bitterness of the quinolones in oral liquid formulation. 
34. Patent Application wo 01/5284869 disclosd a taste masked oral 
formulation linezolid which can be formulated as a suspension a fast 
disintegrating, effervescent or chewable tablet, by microencapsulating the 
antibiotic by solvent evaporation of ethyl cellulose with an optimal seal coat of 
shellac and further coating the particles by functional polymer Eudragit L-30 D.  
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35. Patent Application  wo 01/5844970 disclosed the water dispersible powder 
and tablets of paroxetine for the immediate release of the drug and a taste 
masking agent comprising of the methacrylic acid copolymer. The taste masked 
composition was obtained by spray drying of paroxetine and the polymer.  
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AIM, OBJECTIVE AND PLAN OF WORK 
  
 
AIM OF THE PRESENT STUDY 
Aim of the present study is development and evaluation of taste masked 
Roxithromycin oral suspension. 
 
OBJECTIVE OF THE PRESENT STUDY 
The objective of the present study is to mask the bitter taste of a candidate 
drug of Roxithromycin for suspension. 
 Oral suspensions are suitable for those people who cannot swallow the 
tablets or in case of pediatrics. In such cases oral suspension is the choice. At the 
same time the candidate drug is very bitter in taste so its taste should be masked 
prior to dosage form development. 
 
Desired characteristics of final product: 1 
 It should have an acceptable taste and appearance. 
 The taste, pH,Viscosity, Colour and flavour of the oral suspension must 
be stable throughout the shelf life. 
 It should be free from microorganisms. 
 
PLAN OF THE PRESENT STUDY 
 The study was planned to carry out as follows 
 Literature survey 
 Preformulation study 
  Physical characterization of active-solubility 
 Taste masking of drug by Drug-Resin Complexation 
  Preparation of suspension. 
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 Evaluation of Suspension 
• Taste 
• pH 
• Viscosity 
• Sedimentation volume  
• Assay 
• Dissolution study  
•  Microbial testing 
• Stability testing  
 
 
 
 
 
 
 
Profiles 
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DRUG PROFILE71, 72  
 
Drug name  :  Roxithromycin 
 
Structural formula  
 
 
 
Chemical name  : (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-d- 3-
    hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-
    (2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan- 
                                                2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-    
                                                hexamethyl-1-oxacyclotetradecan-2-one 
     
Emperical  formula :  C41H76N2O15 
Molecular weight  : 837.05 
Functional category : Semi-synthetic macrolide antibiotic 
 
TYPICAL PROPERTIES 
Description   : White crystalline powder. 
 
Melting Point  : 115 - 1200C 
Solubility   :  Freely soluble in ethanol and in acetone,         
   Soluble in methanol, sparingly soluble  acetonitrile,             
   Practically insoluble in water. 
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Contra indication            :  Hypersensitivity to Roxithromycin or other macrolides 
 
 
Adverse effect            :  Blood disorders, Immune system disorders,Nervous      
  system disorders, Cardiac disorders, gastrointestinal                    
  disorders, Hepatobiliary disorders, General disorders. 
 
 
Administration   :  150 mg every 12 hours before food. 
 
 
PHARMACOKINETICS  
 
  Bioavailability is almost 100% 
 Peak plasma concentration is achieved in 2 hours after a dose of 150 mg by mouth. 
 The plasma half-life ranges from 12 hours. 
 About 96 % bound to alpha-1-acid glycoprotein. 
 Partly metabolised in the liver 
 More than 50 % of the dose being excreted in the faeces as unchanged parent drug. 
The remainder is excreted in the urine  
 The average elimination half-life is 10.5 hours, but may be prolonged in children, in 
patients with hepatic impairment (25 hours), in the elderly (27 hours) and in the renal 
impaired (18 hours). 
 Transmission to the cerebrospinal fluid is slow.  
 
THERAPEUTIC USES  
 To treat respiratory tract, urinary and soft tissue infections  
 It also possess anti malarial activity. 
  Disease  Profile 
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DISEASE PROFILE 73 
             Roxithromycin is used to treat various infections caused by bacteria.  
 Acute Pharyngitis (sore throat and discomfort when swallowing.  
 Tonsillitis.  
  Sinusitis.  
  Acute bronchitis (infection of the bronchi causing coughing).  
 Pneumonia (lung infection characterised by fever, malaise, headache).  
  Skin and soft tissue infections.  
  Non gonococcal urethritis.  
 Impetigo (bacterial infection causing sores on the skin). 
PHARYNGITIS 
Pharyngitis is a sore throat caused by inflammation of the back of the 
throat. Pharyngitis or sore throat is discomfort, pain, or scratchiness in the throat. It 
often makes it painful to swallow. 
CAUSES   
Most sore throats are caused by viruses, although a few are due to bacterial 
infections. Bacteria or a virus that are spread in the air when someone sneezes or 
coughs, or you can transfer the organisms to your mouth or nose by touching a 
surface with germs on them. Viruses that can cause sore throat include the common 
cold, the flu, and mononucleosis (often called "mono"). Bacteria like Group 
A streptococcus (commonly known as strep throat) can also cause Pharyngitis. 
SIGNS AND SYMPTOMS 
The symptoms that accompany a sore throat can vary, depending on what 
the underling illness is, 
 Sore throat with cold 
• Sneezing 
• Cough 
  Disease  Profile 
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• A low fever (less than 102 °F) 
• Mild headache 
 Sore throat with flu 
• Fatigue 
• Body aches 
• Chills 
• Fever higher than 102 °F 
 Sore throat with mononucleosis 
• Enlarged lymph nodes in neck and armpits 
• Swollen tonsils 
• Headache 
• Loss of appetite 
• Swollen spleen 
• Liver inflammation 
RISK FACTORS 
Risk factors for Pharyngitis include 
• Cold and flu seasons 
• Having close contact with someone who has a sore throat or cold 
• Smoking or exposure to second hand smoke 
• Frequent sinus infections 
• Allergies 
DIAGNOSIS 
 
• Checking the temperature  
• Examine throat, sinuses, ears, nose, lungs, and neck, including feeling for 
swollen lymph nodes that may indicate strep throat.  May take a throat 
culture or do a rapid strep test by taking a swab from throat.  
• A blood test may be done to check for mononucleosis. 
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PREVENTIVE CARE 
• Avoid kissing or sharing cups and eating utensils with anyone who has a sore 
 throat, a cold, flu, mononucleosis, or bacterial infection. 
• Wash your hands frequently. 
• Don't smoke, and avoid exposure to second hand smoke. 
• Use a humidifier if the air in your home is dry. 
TREATMENT APPROACH 
• Gargling with salt water. 
• Counter pain reliever such as acetaminophen (Tylenol) or ibuprofen (Advil, 
Motrin). 
LIFESTYLE 
• Rest 
• Fluid intake. Water and warm broths are better than soft drinks. 
• Avoid drinking alcohol. 
• Gargle several times per day with ½ teaspoonful of salt in a glass of warm 
 water 
• Try throat lozenges (do not give to a child under 3 years old due to choking 
 hazard). 
MEDICATIONS                                                                                                            
           If   patient have sore throat due to bacterial infection, Roxithromycin is the 
most commonly prescribed drug. 
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EXCIPIENT PROFILE 
CITRIC ACID MONOHYDRATE74 
 
Synonym  : Hydroxypropane – 1, 2,3-tricarboxylic acid  
 monohydrate. 
 
Chemical name :  Hydroxy-1, 2,3-propanetricarboxylic acid  
    monohydrate. 
 
Emperical formula  :  C6H8O7.H2O 
 
Molecular weight : 210.14 
 
Structural formula : 
 
CH2
C COOHHO
CH2 COOH
COOH
. H2O
 
 
Description  : Colourless translucent crystals. White crystalline,  
    effervescent powder.Odorless, strong acidic taste, Crystal 
    structure is ortho rombic. 
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TYPICAL PROPERTIES  
pH   :  2.2 (1% w/v aqueous solution) 
Density  :  1.542 g/cm3  
Melting point :  1000C (Softens at 750C) 
Solubility  :   Soluble in 1.5 parts of ethanol (95%) and 1 in less  
        than 1parts of H2O, sparingly soluble in ether. 
Viscosity  :  6.5Mpas for a 50% w/v aqueous solution at 250C 
Incompatibilities :  It incompatibles with potassium tartrate, alkali and  
      alkaline earth carbonates, and bicarbonates, acetates  
                                     and sulfides, sucrose may crystallize from syrups in the presence       
                                     of citric acid.  
 
Functional category  
 Buffering agent 
 Chelating agent 
 Acidifying agent 
 Flavouring agent 
 Flavour enchancer 
Applications: 
• It is widely used in pharmaceuticals, formulations and food products primarily 
adjust the pH of the solution. 
• It is available as monohydrate and anhydrous material. 
• Citric acid monohydrate : Preparation of effervescent granules 
• Citric acid anhydrous : Preparation of effervescent tablets. 
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  SUNSET YELLOW FCF74 
 
Synonym  :  6-Hydroxy-5-[C4-sulfopheny1) azo]-2-napthalene  
sulfonic acid disodium salt; 1-p-sulfophenyl azo-2-    
napthanol-6-sufonicacid disodium salt; yellow oranges. 
Empirical formula :  C16H10N2Na2O7S2 
Molecular weight : 452.37 
Structural formula : 
NNaO3S N
HO
SO3Na  
Appearance  : Reddish yellow powder, aqueous solutions are  
bright orange coloured.           
           
Solubility  : 
Table-1: Solubility Profile 
SOLVENT SOLUBILITY AT 25° C UNLESS 
OTHERWISE STATED 
Acetone 1 in 38.5 
Ethanol (75%) 1 in 333 
Glycerin  1 in 5 
Propylene glycol 1 in 45.5 
Propylene (50%) 1 in 5 
Water 1 in 5.3 at 2°c 
1 in 5.3 at 25°c 
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Incompatabilities : Poorly compatible with citric acid, saccharine  
    solutions and saturatred sodium bicarbonate  
solutions. 
Incompatible with ascorbic acid, gelatin and glucose. It’s a 
mono azo dye. 
pH   : 1.3 
 
Applications   
 The primary purpose of colouring agent is too visually after the appearance of a 
medicinal product by imparting a definite colour. 
 The use of colour in medicinal products is conjugation with other factors. Such 
as shape and packing, additionally serves to reinforce brand image and identity. 
 It can also serve to introduce a uniformity of appearance to a product. 
 Dyes (Soluble in H2O) 
 Pigments (Insoluble in H2O) 
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  METHYL PARABEN74 
 
Synonym  : 4 – hydroxyl benzoic acid methyl ester; Methyl  
    Chemosept; Methyl p – hydroxybenzonate; Methyl  
    parahydroxybenzonate; Methyl Para sept. 
Chemical name : Methyl 4 – hydroxy benzoate 
Empirical formula : C8H8O3 
Molecular weight : 152.15 
Structural formula : 
COOCH3
OH  
Functional Category : Antimicrobial preservative 
Description   : Colourless crystals, White crystalline powder 
     Odourless, Slight burning taste 
Incompatibilites  : Antimicrobial activity of methyl paraben and other  
 paraben is considerably reduced in the presence of 
 non-ionic surfactants (Polysorbate 80). 
 Incompatibile with other substances such as
 bentonite, Magnesium trisilicate, talc, tracaganth, 
 sodium alginate, essential oils, sorbital and atropine. 
Applications             : Antimicrobical preservative in cosmetics, food 
 products, pharmaceutical formulations. 
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 PROPYLENE GLYCOL74 
Synonym   : 1, 2- Dihydroxy propane; 2-hydroxy propanol;  methyl      
                                               glycol; propane-1,2-diol 
 
Chemical name  : 1, 2-propanediol 
Emperical formula  : C3 H8O2 
Molecular weight  : 76.09 
Structural formula  : CH3CHOHCH2OH 
Functional Category :  Antimicrobial preservative, disinfectant, stabilizer for     
    vitamins, Humectant water miscible co-solvent,     
                                                plasticizer.      
Description   :  Clear, colourless, viscous, partially colourless  
   liquid with a sweet, slightly acrid taste resembling    
   glycerin. 
TYPICAL PROPERTIES  
Density   :  1.038  g/cm3  at 50°C 
Melting point  :  -59°c 
Boiling point   :  188°C 
Viscosity   :  58.1 mpas at 50°C 
Solubility   :  Miscible with acetone, chloroform, ethanol (95%)  
       glycerin, water. Soluble 1 in 6 parts of ether not miscible 
       with light mineral oil, Dissolve some essential oils. 
Incompalbillties  : It is incompatible with oxidizing reagents such as  
     Potassium  permanganate. 
Applications  : It is widely used as a solvent, extractant, preservative 
     in a  variety of parenteral and non parenteral             
                                                  pharmaceutical formulations. 
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 SODIUM CHLORIDE74 
Synonym  : Common salt; Natural halite; rock salt;  
salt; sea salt; table salt. 
Chemical name :          Sodium chloride. 
Emperical Formula: NaCl 
Molecular Weight : 58.44 
Structural Formula: NaCl 
Description  : White crystalline powder, 
Odorless crystals, 
It has saline taste, 
The crystal lattice is a face Centred cubic structure. 
TYPICAL PROPERTIES  
pH   : 6.7-7.3 
Boiling point  : 1439°C 
Density  : 2.17g/cm3 1.20g/cm3 for saturated aqueous solution. 
Bulk density  : 0.93g/cm3 
Tapped density : 1.09g/cm3 
Solubility  : Slightly soluble in ethanol, 
         1 in 2.8 parts soluble in water, 
         1 in 2.6 parts soluble in water at 100°C 
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Stability and Storage : Aqueous sodium chloride solutions are stable but  
may cause the separation of glass particles from certain types           
of glass container. The solid material is stable and should be  
                                       stored  in a well closed  container, in a cool dry place. 
Incompatibilities     : Aqueous sodium chloride solutions are corrosive to  
                                        iron. They also react to form precipitate with silver, lead and       
                                        mercury salts. 
                                        Story oxidizing agents liberate chlorine from acidified         
                                        Solutions of NaCl. The solubility of the antimicrobial                       
                                        preservative methyl paraben is decreased in aqueous NaCl           
                                        solutions. 
Applications   
 It is   widely used in a variety of parenteral and non parenteral pharmaceutical 
formulations. 
 It is  used to control drug release from microcapsules. 
 It can used adjust the viscosity of polymer. 
 It is used as a lubricant and diluent. 
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  SODIUM BENZOATE74 
Synonyms  : Benzoate of soda; Benzoic acid sodium salt. 
Chemical name : Sodium benzoate 
Empirical formula : C7H5NaO2 
Molecular weight : 144.11 
Structural formula :  
COONa
 
 
Functional category : Antimicrobial  preseravative, Tablet and capsule lubricant. 
Description    :  It occurs as a white granular, crystalline, slightly  
hygroscopic powder, odorless. It has an unpleasant, sweet 
and saline taste. 
 
TYPICAL PROPERTIES  
pH   : 8.0 (saturated aqueous solution at 25°C) 
Density  : 1.15  g/cm3 at 24°C 
Solubility  : Ethanol (75%) soluble 1 in 75 parts at 25°C) 
Ethanol (70%) soluble 1 in 50 parts  at 25°C) 
 
Stability and storage conditions : Aqueous solutions may be sterilized by  
     autoclaving. The bulk material should be  
     stored in a well  closed container in a cool, dry place. 
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Incompatibilities : Incompatible with quaternary compounds, gelatin,  
ferric salts, calcium salts and salts of heavy metals including 
silver, lead and mercury.  
Non-ionic surfactants may be reduced by interactions with 
kaolin. 
Applications     
 Antimicrobial preservative in cosmetics, food and pharmaceuticals. 
 It is used in concentration of 0.02-0.5% in oral medicines 0.1-0.5% in cosmetics. 
 It may impart an unpleasant flavour to the product. 
 It is used as a Tablet lubricant. 
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 SODIUM CITRATE DIHYDRATE 74 
 
Synonyms  : Citric acid trisodium salt; trisodium citrate. 
Chemical Name : Trisodium 2-hydroxy propane -1,2,3,-tricarboxylate  
  dihydrate. 
Emperical formula : C6H5Na3O7.2H2O 
Molecular weight : 294.10 
Structural Formula   
CH2
C COONaHO
CH2 COONa
COONa
. 2H2O
 
Functional Category : Alkalizing agent, Buffering agent, Sequestering  
     agent        
Description   : Sodium citrate dihydrate consists of odourless,  
 colorless, white crystalline powder with a cooling 
 saline taste, slightly deliquescent in moisture. 
TYPICAL PROPERTIES  
 
 pH   : 7-9 (5% W/V aqueous solution) 
 Density  : 1.19g/m3 
 Melting Point : Converts to the anhydrous form at 150°C 
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 Solubility  : Soluble 1 in 1.5 parts of H2O, 1 in 0.6 parts of Boling 
     water. Practically insoluble in ethanol (95%) 
     Incompatibilities   
 Aqueous solutions are slightly alkaline and will react with acidic substances. 
 Calcium and strontium salts will cause precipitation of the corresponding 
citrates. 
 
Applications   
 It is a anhydrous material is widely used in pharmaceutical formulations and 
food products primarily to adjust the pH of the solutions. 
 It is also used as a sequestering agent. 
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  SORBITOL74 
Synonym  : 1,2,3,4,5,6,-heanehexol; hydox; neosorb; sorbite;  
  D-sorbitol; sorbitol instant. 
Chemical name : D-Glucitol 
Empirical formula : C6H14O6 
Molecular weight : 182.17 
Structural formula : 
CH2OH
OHH
HOH
OHH
OHH
CH2OH
 
 
Functional category : Humectants,  
Plasticizer,  
Sweetening agent,  
Tablet and capsule diluents. 
Description             Odourless, white crystalline, hygroscopic powder,Sorbitol      
                                            has a pleasant cooling ,sweet taste and has a approximately       
                                           50-60% of the sweetness of sucrose 
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TYPICAL PROPERTIES  
 
pH   : 4.5-7.0 
Density  : 1.49 g/cm3 
Melting point : 110-112°C for anhydrous from. 
97.7° C for monohydrate. 
                    93°C for metastable monohydrate form. 
Solubility  : Practically insoluble in Chloroform and ether at  
    25° C. Slightly soluble in Methanol at 25°C                
          Soluble 1 in 0.5 part in Water at 25°C 
 
Incompatibilities : Sorbitol will form water soluble chelates with many  
di-and-trivalent metal ions in strongly acidic and alkaline 
conditions. 
 
Applications   
 Sorbitol is widely used as an excipient in pharmaceutical formulations. 
 It is also used extensively in cosmetics and food products. 
 It is used as a vehicle in sugar free formulations and a stabilizer for a drug 
(Vitamin and antacid suspensions). 
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SUCROSE74 
Synonym  : Beet sugar; cane sugar; α-β glucopyranosyl- β-D- 
   fructofuranoside; refined sugar; saccharose; sugar 
 
Chemical name : β-D-fructofuranosyl- α-β glucopyranoside 
Empirical formula : C12H22O11 
Molecular weight : 342.30 
Structural formula : 
O
OH
OH
CH2OH
CH2OH
CH2OH
OH
O
O
 
 
Functional category : Base for medicated confectionery, 
Granulating agent, 
Sugar coating adjuvant, 
Suspending agent, 
Sweetening agent, 
Tablet and capsule diluents, 
Viscosity increasing agent. 
 
Description   :   It is colourless crystals, crystalline powder, Odourless   and 
          sweet taste. 
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TYPICAL PROPERTIES   
Density  : 1.56  g/cm3 (Crystalline sucrose) 
1.56 g/cm3   (Powdered sucrose) 
Density (bulk) : 0.93 g/cm (Crystalline sucrose) 
0.60  g/cm3 (Crystalline sucrose) 
Density (tapped) : 1.03  g/cm3 (Crystalline sucrose) 
0.82 g/cm3   (Powdered sucrose) 
Melting point : 160 -186°C (with decomposition) 
Solubility  : Practically insoluble in Chloroform at 20°C 
Soluble in 1 in 0.5 parts of Water at 20°C  
Incompatibilities :   It may be contaminated with traces of heavy metals which can   
         lead to in compatible with active ingredients.Eg Ascorbic   
         acid. 
                                      It is also incompatible with aluminium. 
 
Applications  : 
 It is widely used in oral pharmaceutical formulations. 
 Sucrose syrup containing 50-67 % w/w sucrose. 
 Binding agent wet granulation in the tableting. 
 Large amount of sucrose may harden to give poor disintegration  
in the tablet manufacturing. 
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GLYCERIN74 
Synonym          : Croderol; glycerine; glycon G-100; kemstrene;  
pricerine;1,2,3,-propanetriol; trihydroxy propane glycerol 
Chemical name          : Propane-1,2,3-triol 
Emperical Formula        :  C3H8O3 
Molecular Weight         : 92.09 
Structural formula           
CH2OH
HC OH
CH2OH
 
Functional category : Antimicrobial preservative, 
 Emollient, 
 Humectant, 
 Plasticizer,  
 Solvent, 
 Sweetening agent, 
 Tonicity agent. 
Description  : Clear, colorless, odorless, viscous, hygroscopic     
 liquid, it has a sweet taste, approximately 0.6 times as 
sweet as sucrose. 
TYPICAL PROPERTIES 
Boiling point  : 290°C 
Density  : 1. 2656 g/cm3at 15°C 
           1. 2636 g/cm3at 20°C 
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1. 2620 g/cm3at 25°C 
Melting point : 17.8°C 
Solubility  : Slightly soluble in Acetone 
Practically insoluble in Benzene 
Miscible with Ethanol(95%) and Water 
Incompatibilities : It may explode if mixed with strong oxidizing  
agents, such as chromium trioxide and potassium chlorate. 
Black discoloration of glycerine occurs in the presence of 
light on contact with zinc oxide. 
Applications   
 
 It is also used in cosmetics and as a food additive.  
 It’s used as a therapeutic agent in a variety of clinical applications. 
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PROPYL PARABEN74 
Synonym  : 4 – hydroxyl benzoicacid propylester; propyl p- 
hydroxy benzoate; propyl para hydroxy benzoate; propyl 
paracept 
Chemical Name : Propyl 4 –hydroxy benzoate   
Empirical formula : C10H12O3  
Molecular Weight : 180.20 
Structural formula  
O
O
HO
CH2
H2C CH3
 
Functional Category : Antimicrobial preservative  
TYPICAL PROPERTIES  
Solubility  : Freely soluble in Acetone and Ether at 25°C 
Soluble in Water in 1 in 25  parts at 80°C 
Description  : White, crystalline, odourless and tasteless powder 
Incompatibilities :  The antimicrobial activity of propyl paraben  
considerably reduce in the presence of non ionic surfactants 
as a result of micellization. Absorption of propyl paraben by 
plastics has been reported. Propyl paraben is discoloured in 
the presence of iron. 
Applications   
 It is used as an antimicrobial preservative in cosmetic formulations. 
 Propyl paraben (0.02%) together with methyl paraben (0.18 %) has been 
used for the preservation of varios parenteral pharmaceutical 
formulations. 
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TWEEN 8074 
Synonym  : Polyoxyethylene 20 oleate 
Chemical name : Poly oxy ethylene 20 sorbitan oleate 
Empirical formula : C64H124O26  
Molecular Weight : 1310 
Functional category: Emulsifying agent, 
Non-ionic surfactant, 
Solubilizing agent, 
Wetting agent. 
Description  : It have a characteristic odour, warm, bitter taste,  
   yellow oily liquid form at 25°C 
TYPICAL PROPERTIES   
Moisture content : 3.0(%) 
HLB value  : 15.0 
Viscosity  : 425 mpas 
Specific gravity : 1.08 at 25°C 
Solubility  : Soluble in Ethanol and Water 
    Insoluble in mineral oil and Vegetable oil  
Incompatibilities : Discoloration and precipitation occurs with various  
Substances, especially phenols, tannins, tar-like materials. 
The antimicrobial activity of paraben preservatives is 
reduced in the presence of polysorbates. 
Applications   
 Hydrophilic non-ionic surfactants used widely as emulsifying agent in the 
preparation of stable oil in water pharmaceutical emulsion.  
 It may also be used as solubilizing agents. 
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XANTHAN GUM74 
Synonym  : Corn sugar gum, poly saccharide 
Chemical name : Xanthan gum 
Empirical formula : It is a high molecular weight polysaccharide gum.  
It contains D-glucose, D- mannose as the dominant hexose 
units along with D- glucuronic acids. 
Functional Category: Stabilizing agent, Suspending agent, Viscosity-  
    increasing agent. 
Description  : Cream or white coloured, odourless, free flowing fine  
    powder. 
     
TYPICAL PROPERTIES  
Activity / Alkalinity : pH – 6-8 for 1 % w/v aqueous solution  
Melting Point : Chars at 270 °C 
Solubility  : Practically insoluble in ethanol and ether, 
Soluble  in cold and warm  water. 
Viscosity  : 120-1600 cps for 1 % w/v aqueous Solution  at 25°C 
Incompatibilities : Xanthan gum is an anionic material is not   usually  
Compatible with cationic surfactant. Polymersand 
preservatives since precipitation occur. It is compatible with 
most synthetic and natural viscosity increasing agents. It 
must be stable in the presence of 60% water miscible 
organic solvents. 
Applications   
 It is used in Oral and topical pharmaceutical formulations, cosmetics and food 
products. 
 It is also used as a suspending and stabilizing agent 
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INDION -204 75 
Matrix type       : Derived from cross linked poly acrylic acid 
Functional group      : Carboxylic acid  
Standard ionic form   : H+ 
SPECIFICATIONS PHYSICAL PROPERTIES 
Particle size range     : ≤0.15 
% moisture      : ≤ 5 
Total exchange Capacity meq/g(dry) : 10.0 
Solubility  : Insoluble in water and common solvents. 
Appearance  : White to off white flowing powder. 
Chemical properties : Polymeric functional group –carboxylic acid  
Applications  : Taste Masking Agent: A drug polymer adduct can be  
    synthesized due to the ionic bond between the bitter and the 
    polymer thus masking the objectionable bitter taste of the 
    drug since the polymer drug adduct is formed. It is tasteless 
    in the mouth, but it dissociates in the acidic pH of the  
    stomach, the bio availability of the drug is not affected.  
Toxicity  : It is a high molecular weight polymer so can’t be  
absorbed by body tissue and it is safe for human 
consumption. It has no any physiological action 
recommended dosage and it is non –toxic. 
Storage  : Stored in a tightly container, keep away from the  
moisture, moisture is absorbed drug at 900° c to 1000°C to 
remove moisture content below 10%  
Packing  : 5 kg, 20 kg in corrugated box. 
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methods 
 
Materials and Methods 
 
Department of Pharmaceutics, Madras Medical College  Page 47 
 
MATERIALS AND METHODS 
Table 2:List of materials and their applications in formulation. 
Name of the 
material Manufacturer/ supplier 
Use in 
formulation 
Roxithromycin IP Apex Laboratories P Ltd Active 
Ingredient 
Indion-204 Ion exchange (India) Ltd, Mumbai Cation Exchange 
Resin 
Sucrose Cooperative sugar mills (Pvt) Ltd, Pondy Sweetener 
Sorbitol Solutions 
(70%) 
Gayathri starch kem Ltd, Andra 
Pradesh Sweetener 
Xanthan gum D.K.Enterprises(Archerdaniersmidland 
company), USA 
Suspending 
Agent 
Propylene glycol IP Manali petro chemicals (Pvt) Ltd, Chennai 
Solvent for 
preservative 
Sodium Benzoate IP Ganesh Benzo Plast, Uma Lakshmi 
and Co, Chennai Preservative 
Methyl paraben IP Salicylates Chemicals, Hyderabad Preservative 
Propyl Paraben IP Salicylates Chemicals, Hyderabad Preservative 
Citric Acid 
monohydrate Solaris Bio Chemicals Ltd, Vadodra Acidulant 
Sodium Citrate IP Sunil chemicals, Uma Lakshmi and Co, Thane Dist Buffering agent 
Sodium chloride Southern fine kem India Ltd.,Chennai Electrolyte 
Glycerin Godrej industries Ltd,Mumbai Viscosity builder 
Sunset Yellow FCF Roha dye chem, Indiras agencies, 
Maharastra Colouring agent 
Tween-80 Laffans petro chemicals Ltd, Gujrat Wetting agent 
Masking Flavour 
2521 
Firmenich aromatics India (Pvt)Ltd, 
Daman Flavouring agent 
Orange oil Flavour Firmenich aromatics India (Pvt)Ltd, 
Daman 
Flavouring agent 
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Table 3: List of Instruments/Equipments used 
S.No Instruments/Equipments Manufacture/ Supplier 
1. Electronic weighing balance Shimadzu, Japan 
2. Brook Field Digital Viscometer Brook Field, German  
3. pH Meter Digisun Electronics, Hyderabad 
4. Dissolution Test Apparatus Veego (VDA-60) 
5. UV- Visible Spectrophotometer UV Pharma Spec1700, SHIMADZU 
6. Water bath In Lab Equipments (Chennai) Pvt. Ltd 
7. Humidity chamber In Lab Equipments (Chennai) Pvt. Ltd 
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The objective of the present work to be achieved in the following steps. 
 Preformulation studies 
 Complexation of  drug  with Resin 
 Development of suspension  
 Evaluation of suspension 
 Stability studies  
 
Preformulation studies 76 
               Preformulation investigations are designed to deliver all necessary 
data (especially physicochemical and Biopharmaceutical properties of drug 
substance, excipients and packaging materials) which may influence 
 
 Formulation design 
 Method of manufacture of drug substance and drug  product 
 Pharmacokinetic/Biopharmaceutic properties of the resulting product 
 Packaging of the product 
 
Preformulation steps: 
 
1.  Calculation  of many of the important physico-chemical characteristics of  
drug – Solubility. 
   
PROCEDURE  
  Solubility of API and the excipients in different selected media was 
determined by dissolving the known quantity in cumulative manner with the aid 
of sonication till the API or the excipients remains insoluble in the media. 
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Preparation of 0.1N Hydrochloric Acid (1.2pH)  
  8.5ml of the hydrochloric acid was taken and dissolved in water and 
made upto 1000ml to get 0.1N hydrochloric acid. 
 
DETERMINATION OF λmax 77 
   30g of Ammonium acetate was dissolved in 50 ml of water. 1 
ml of Acetyl acetone was added and the final volume was adjusted to 100ml 
with water and stored in refrigerator. Freshly prepared reagent was used in the 
analysis. 250mg of Potassium permanganate was dissolved and diluted to 100 
ml with water. 10gm of Oxalic acid was dissolved and diluted to 100ml with 
water. 250mg of Roxithromycin   was accurately weighed and transferred to a 
100ml volumetric flask. It was dissolved in 20ml of glacial acetic acid and 
diluted to 100ml with distilled water. 5ml 0f an aliquot was further diluted in 
50ml of water to obtain the final concentration of 250 µg/ml. 
   In a 10ml volumetric flask, 2ml of standard Roxithromycin 
solution and 1ml glacial acetic acid solution were pipetted successively. 0.2ml 
of potassium permanganate solution was added. The reaction mixture was 
heated on water bath at 37°C for 10min. Excess of potassium permanganate 
was neutralized with oxalic acid. 2ml of reagent solution was added to it and 
mixed thoroughly. The reaction mixture was heated on water bath at 37°c for 
1min and cooled. The volume was adjusted upto the mark with water. 
Absorbance of the coloured solution was scanned on UV-Visible 
spectrophotometer from 600nm to 200nm against reagent blank. Maximum 
absorbance was obtained at 412nm. 
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PREPARATION OF CALIBRATION CURVE  
  25mg of Roxithromycin was weighed accurately and transferred to a 
100ml standard flask. To that 1ml of Hydrochloric acid was added and the 
volume was made upto the mark using deionized water. From the stock solution 
2, 4, 6, 8 and 10ml was pipetted out in a 10ml standard flask. To each of the 
standard flask, 0.2ml of potassium permanganate solution was added. The 
mixture was heated on water bath for 10 min at 37 ⁰C. Excess of potassium 
permanganate was neutralized with oxalic acid. 2ml of reagent solution was 
added to it and mixed thoroughly. The mixture was heated on water bath for 1 
min at 37⁰ C and cooled. The volume was adjusted upto the mark with 
deionized water. Absorbance of the solution was measured against a reagent 
blank at 412nm.  
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FORMULATION DEVELOPEMENT  
 Following ingredients were selected to develop the desired formulation. 
Table 4: Formulation of suspension 
S.No Ingredients S-1 S-2 S-3 S-4 S-5 S-6 S-7 
1 Roxithromycin (g) 10 10 10 10 10 10 10 
2 Indion-204 (g) 2.5 5 7.5 10 20 25 30 
3 Sucrose (g) 300 300 300 300 300 300 300 
4 Xanthan gum (g) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
5 Tween 80 (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
6 Sorbitol (g) 100 100 100 100 100 100 100 
7 Propylene glycol (g) 50 50 50 50 50 50 50 
8 Methyl paraben (g) 1 1 1 1 1 1 1 
9 Propyl paraben (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
10 Sodium citrate (g) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
11 Citric acid  (g) 1 1 1 1 1 1 1 
12 Sodium chloride (mg) 1.25 1.25 1.25 1.25 1.25 1.25 1.25 
13 Glycerin (g) 50 50 50 50 50 50 50 
14 Mint flavour (ml) 10 10 10 10 10 10 10 
15 Orange oil flavour  (ml) 5 5 5 5 5 5 5 
16 Sunset yellow FCF (mg) 25 50 50 50 50 50 50 
17 DM Water q.s q.s q.s q.s q.s q.s q.s 
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PROCEDURE 78 
Step -1   
  Drug and ion exchange resins were weighed accurately. Then the resin was 
poured into DM water.  The drug was added in to the resinate with continuous 
stirring to get drug resinate. 
Step -2 
 Sucrose was added to 150 ml of DM water and boiled for complete 
dissolving of sucrose. Then the sorbitol was mixed with the sugar solution. 
Step -3  
  Xanthan gum was poured in to glycerin and mixed to dissolve the gum 
completely. 
Step-4 
  Tween 80 was added in to the drug resinate. The sugar, sorbitol solution 
and xanthan gum solution were added in to the drug resinate formulation.  
Step -5  
  Methyl paraben and propyl paraben were added separately  into propylene 
glycol and dissolved completely. This was added to the drug resinate 
formulation.  
Step-6 
 Sodium citrate, citric acid and sodium chloride were dissolved in DM water 
and  poured in to the drug resinate formulation.  
Step-7 
 The flavors and colour were added into the drug resinate formulation. 
Finally suspension was made up to 1000 ml with DM water and mixed for 30 
minutes. 
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EVALUATION OF SUSPENSIONS 
Taste evaluation of optimized formulation79 
  The taste evaluation was performed with 10 volunteers in the age 
group of 19-25 yrs. The Formulation (S-7) was held in the mouth for 15 
seconds by each volunteer and the bitterness level was recorded against pure 
drug using a numerical scale. 
 
pH  
  pH is be defined as the negative logarithm of hydrogen ion 
concentration. 
 Mathematically it is written as  
pH = log   1/ [H3O+] 
 Since the logarithm of 1 is zero. 
           The equation may also be written   
   pH =  - log(H3O+) 
 
 Determination of pH 80 
 pH of suspension was determined by using pH meter. pH of the phases of 
suspension also contributes to stability and characteristic of formulations. pH of 
the suspension was recorded from time to time. 
 
Viscosity  
 Viscosity of suspension is a great importance for stability and palatability 
of suspensions. Suspensions have least physical stability amongst all dosage 
forms due to sedimentation and cake formation.78 
 Sedimentation is governed by stoke’s law, 
V = d2 (ρs – ρl ) g / 18 n 
 
Materials and Methods 
 
Department of Pharmaceutics, Madras Medical College  Page 55 
 
V - terminal settling velocity 
d –diameter of the settling particle 
ρs – density of the settling solid (dispersed phase)  
ρl - density of the liquid (dispersion medium) 
g – Acceleration due to gravity 
Ƞ – viscosity of dispersion medium 
when the viscosity of dispersion medium increases the settling velocity 
decreases. 
 
 Determination of viscosity81 
  The viscosity of suspension was determined at ambient condition using 
Brookfield digital viscometer taking adequate amount of the sample.  
 
Sedimentation Volume 80 
 Sedimentation volume F is the ratio of equilibrium volume of sediment 
(Vu) to the total volume of suspension (Vo).77 
F  =  Vu / Vo 
                        Vu   - Volume of sediment  
        Vo   - total volume of suspension 
 The sedimentation volume F normally ranges from less than 1 to 1. When 
F=1, the sediment volume and the total volume are equal and such a suspension 
is pharmaceutically acceptable. 
 
 Determination of sedimentation volume 80 
 Sedimentation volume was determined as a function of time. 50ml 
suspension was transferred to a 100 ml measuring cylinder of 2.5cm diameter. 
The sedimentation volume F was determined. 
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Assay77, 79 
  Accurately measured volume (5ml) of suspension was transferred to 
a 50ml volumetric  flask, the volume was made up with 0.1N HCl to break the 
complex and sonicated for 30min. To the above solution 0.2ml of potassium 
permanganate was added and heated for 10 mins at 37⁰C. The excess of 
potassium permanganate was neutralized with oxalic acid. To the resulting 
mixture, 2ml of reagent solution was added and heated at 37⁰C for 1 min. The 
absorbance of the resulting solution was measured at 412nm taking a reagent 
blank. 
In vitro Dissolution study 77, 79 
 Dissolution profile of Roxithromycin suspension was determined using the 
USP (type II) paddle apparatus with a speed of 50 rpm. Dissolution was tested 
in acidic buffer 0.1N HCl of 900ml at 37 ±0.5˚C. Aliquot volume was 
withdrawn at 10, 20, 30 and 60 min and filtered throught 0.45µ membrane 
filter. To that 0.2ml of potassium permanganate was added and heated for 10 
min at 37⁰C. The excess of potassium permanganate was neutralized with 
oxalic acid. To the resulting mixture, 2ml of reagent solution was added and 
heated at 37⁰C for 1 min. The absorbance of the resulting solution was 
measured at 412nm taking a reagent blank.  
 
MICROBIAL TESTING82 
MICROBIAL TESTING OF FINISHED PRODUCT  
This test is mainly performed to check whether the finished product has any 
presence of micro organism or not. 
For this test two media were commonly employed namely, 
1. Tryptone Soya Agar Medium (TSA) for bacteria.  
2. Sabouraud’s Chloramphenicol Agar Medium (SCA) for yeast and 
moulds.       
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STEPS82 
1. TSA and SCA medium were prepared and autoclaved for 15 min at 121°C. 
2. 10ml of the sample was added to the broth and mixed well. 
3. By using a micropipette, 1 ml from the broth was transferred to two sterile 
 petridishes, One for bacteria and the other for fungi. 
4.  20 ml of the TSA and SCA medium was poured into their respective plates        
5. The plates were then rotated in clockwise and anti-clockwise directions for 
 even spreading of the sample. 
6. The plates were allowed for solidification. 
7. TSA plate was incubated at 37°C for 48 hours in an inverted position. 
8. SCA plate was incubated at 20 -25°C for 5 days in an upright position. 
9. The colonies formed were counted and recorded. 
 
LIMITS82 
  
   Bacteria : not more than 300 colonies per plate. 
    Fungi : not more than 100 colonies per plate. 
 
 
FORMULA (CFU/ML)       =      No.of colonies X Amount of Sample taken   
                                                     Dilution factor 
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PATHOGEN TESTING82 
          This test is done only if the inoculated plate shows coloured colonies 
which indicates the presence of pathogens. 
The pathogens are 
Escherichia coli 
Salmonella species 
The following media were employed. 
a)  Bismuth sulphite agar 
Selective for Salmonella species and produce black coloured colonies. 
b)  Eosin methylene blue agar: 
Selective for E.coli species and produce green coloured  colonies with metallic 
sheen. 
 
STABILITY TESTING 83, 84 
STABILITY STUDIES OF THE FINISHED PRODUCT  
  Stability of a drug can be defined as the time from date of 
manufacture and packaging of the formulation until its chemical or biological 
activity is not less than a predetermined level of labeled potency and its 
physical characteristics have not changed appreciably or deleteriously. 
Although there are exceptions, 90% of labeled potency is recognized as the 
minimum acceptable potency level.83 
      The international conference on Harmonization (ICH) Guideline 
titled “stability testing of new drug substance and products” (QIA) describes the 
stability test requirements for drug registration application in the European 
Union, Japan and USA.84 
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ICH specifies the length of study and storage conditions. 
 Long term testing 25°C ± 2°C /60 % RH ± 5% for 12 months 
 Accelerated testing 40°C ± 2°C/75% RH ±5% for 6 months 
 Refrigerated conditions 5°C ± 3°C.  for 3 months 
  Stability studies for the present work was carried out at 25°C ± 2°C / 
 60% RH and 40°C ± 2°C / 75 % RH for the selected formulation for three 
 months and at 5°C ± 3°C refrigerated conditions for 3 months. 
 
METHOD 
     The selected formulations were packed in wide mouth bottle. They were   
stored at 25°± 2°C /60%± 5% RH and 40° ± 2°C /75%± 5% RH for 3 months in 
humidity chamber and evaluated for their physical appearance and drug content 
at specified intervals of time.  
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RESULTS AND DISCUSSION 
 
PREFORMULATION STUDIES 
 
Solubility Studies 
  
Solubility studies were done for candidate drug and excipients as per requirement 
of development.74 
Table 5: Solubility of ingredients in different solvent 
 
Solute  Ethanol Ether Water Acetone Chloroform 
API  Freely 
soluble 
ND 
 
In soluble 
 
Freely 
soluble 
ND 
Sucrose ND ND Very 
soluble 
ND In soluble 
Xanthan gum In soluble 
 
In soluble soluble 
 
ND ND 
Tween80 Soluble 
 
In soluble soluble 
 
ND ND 
Sorbitol  Slightly 
soluble 
In soluble Very 
soluble 
ND In soluble 
 
Sodium citrate In soluble 
 
ND Freely 
Soluble 
ND ND 
Citricacid 
monohydrate 
Freely 
Soluble 
Sparingly 
soluble 
Very 
soluble 
ND ND 
Sodium chloride  Slightly 
soluble 
ND Freely 
Soluble 
ND ND 
Sodium 
benzoate  
Sparingly 
soluble 
ND Freely 
Soluble 
ND ND 
Glycerin Miscible  ND Miscible  Slightly 
soluble 
In soluble 
 
Propylene glycol Miscible  Soluble 
 
Miscible  Miscible  Miscible  
Methyl paraben Freely 
Soluble 
ND  Slightly 
soluble 
ND ND 
Propyl paraben Freely 
Soluble 
Freely 
Soluble 
 Slightly 
soluble 
ND ND 
* ND – Not Dissolved 
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  Roxithromycin was soluble in ethanol and insoluble in water. All the 
ingredients were soluble in water. 
 CALIBRATION CURVE FOR ROXITHROMYCIN  
                        Table 6:  Data for Calibration Curve of Roxithromycin in 0.1N HCl 
Concentration  
(mcg/mL) Absorbance 
0 0.0000 
2 0.1600 
4 0.3300 
6 0.4970 
8 0.6570 
10 0.8310 
 
 
 
Fig.1: Calibration Curve of Roxithromycin 
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 It was found that the solutions of Roxithromycin in 0.1N Hcl show linearity (R2= 
0.999) in absorbance at concentrations of 2-10mcg/ml and obeys Beer Lambert Law. 
 
FORMULATION DEVELOPMENT  
 
(a) Evaluation of Formulated Roxithromycin Suspension  
 
Table 7:Evaluation of Roxithromycin suspension 
S.No 
Test for 
evaluation 
Observation 
S -1 S - 2 S- 3 S- 4 S -5 S – 6 S - 7 
1 Taste Bitter Bitter Bitter Bitter Bitter Slightly Bitter 
Not 
Bitter 
2 pH 3.54 3.58 3.61 3.67 3.70 3.64 3.66 
3 
Viscosity 
(Cps) 
576 589 632 648 644 652 665 
4 
Sedimentation 
volume (F) 
0.94 0.95 0.96 0.97 0.97 0.99 0.99 
 
Inference 
 Oral suspensions were formulated in different combinations S-1, S-2, S-3, S-4,  
S-5,S-6,S-7 
 From the above formulations, it was found that the bitter taste was not masked for 
formulations S-1, S-2, S-3, S-4 & S-5. 
 Slightly bitter taste was observed in the formulation, S-6. 
  The taste was completely masked in formulation S-7. 
 The pH of formulations S-1 to S-7 ranged from 3.54 to 3.70 and the viscosity 
ranged from 576 to 665 Cps. 
 The sedimentation volume (F) ranged from 0.94 to 0.99. 
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ASSAY 
 
 The drug content of the formulated suspension are given in table 8 
 
Table 8: Assay of formulated Roxithromycin suspension 
S.No Formulation  Drug content (%)* 
1 S -1 98.9 ± 0.0031 
2  S -2 97.85 ± 0.1021 
3  S -3 99.70 ± 0.187 
4  S -4 98.34 ± 0.1542 
5  S -5 99.16 ± 0.0021 
6  S -6 99.89 ± 0.078 
7  S -7 99.78 ± 0.0245 
 
*Mean ±SD (n=3) 
 
INFERENCE 
  The drug content of the suspension ranged from 97.85% to 99.85%.The 
drug content of the formulation were within the limits.79 
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 Table 9: In vitro drug release of formulated Roxithromycin suspension 
   
Time 
 (min) 
 CUMULATIVE % DRUG RELEASE* 
S-1 S-2 S-3 S-4 S-5 S-6 S-7 
10 79.44 ±  0.02       
74.62± 
0.0500 
72.05± 
0.0360  
69.05± 
0.0150 
67.02± 
0.0458 
65.44± 
0.0321 
59.82± 
0.0568 
20 95.81± 0.0057 
91.86± 
0.0206 
83.43± 
0.0264 
80.89± 
0.0046 
80.12± 
0.0251 
78-47± 
0.0300 
75.02± 
0.0512 
30 99.79± 0.0100 
99.88± 
0.0152 
97.92± 
0.0125 
93.25± 
0.0600 
92.22± 
0.0642 
86.19± 
0.0808 
84.02± 
0.0611 
60 - - 99.82± 0.0264 
99.72± 
0.0400 
99.72± 
0.0305 
99.86± 
0.0360 
99.62± 
0.0850 
*Mean ±SD (n=3) 
 
INFERENCE 
 
  As the concentration of the resin was increased, the release of the drug 
from the formulation was sustained. Formulation S-1 & S-2 showed maximum release 
within 30 min.  
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IN VITRO RELEASE STUDIES 
 
Fig. 2: IN VITRO RELEASE PROFILE S-1 
 
 
 
Fig. 3: IN VITRO RELEASE PROFILE OF S-2 
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Fig. 4: IN VITRO RELEASE PROFILE OF S-3 
 
 
 
Fig. 5: IN VITRO RELEASE PROFILE OF S-4 
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Fig. 6: IN VITRO RELEASE PROFILE OF S-5 
 
 
Fig. 7: IN VITRO RELEASE PROFILE OF  S-6 
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 Fig. 8: IN-VITRO RELEASE PROFILE OF S-7 
 
 
 
Fig. 9: COMPARATIVE IN-VITRO RELEASE PROFILE OF  
S-1 to S-7 
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Table-10:  COMPARATIVE EVALUATION OF MARKETED SAMPLE AND  
                                     FORMULATION S-7 
  
 
S.No 
Test for 
evaluation 
Observation 
 
Marketed sample 
 
 Formulation S –7 
1 Taste Slight Bitterness observed Bitterness completely masked 
2 pH 3.68 3.66 
3 Viscosity (Cps) 660 665 
4 
Sedimentation 
volume (F) 0.99 0.99 
5 Colour Orange Pale yellow 
6 
Drug Content * 
(%) 
99.03 ±0.0267% 99.78 ±0.0245% 
*Mean ±SD (n=3) 
 
 
INFERENCE 
 From the comparative study between marketed sample and S7 formulation it was 
found that the bitter taste of Roxithromycin was completely masked in formulations S7. 
The other parameters were found to be the same as with marketed formulation. 
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Table11: COMPARATIVE DISSOLUTION PROFILE OF OPTIMIZED 
FORMULATION S-7 WITH MARKETED SAMPLE 
Time  (min) 
% DRUG RELEASED* 
Marketed sample Formulation S-7 
10 61.98±0.0929 59.82±0.0568 
20 75.35±0.0513 75.02±0.0512 
30 83.98±0.0953 84.02±0.0611 
60 99.79±0.0624 99.62±0.0850 
*Mean ±SD (n=3) 
 
 
The in vitro drug release from the marketed sample and formulation S-7 are 
similar. 
 
 
Fig.10:  IN VITRO RELEASE PROFILE OF MARKETED SAMPLE 
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Fig.11: COMPARATIVE IN VITRO RELEASE PROFILE FOR  
MARKETED SAMPLE AND FORMULATION S-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
Department of Pharmaceutics, Madras Medical College Page 72 
 
MICROBIAL TESTING 
 
Table12: COLONY COUNTING (STABILITY CONDITIONS) 
S.No Observation Accelerated 
condition 
(40±2°C/75±5%RH) 
for 3 months 
Real time 
condition 
(25±2°C/60±5% 
RH) for 3 months 
Refrigeration  
condition  
(5±3°C)for 3 months 
1 BEFORE 
INCUBATION 
a) Total bacterial 
count 
 
Nil 
 
 
Nil 
 
 
Nil 
b)Total fungal 
count 
Nil Nil Nil 
2 AFTER 
INCUBATION 
a) Total bacterial 
count 
 
10 CFU/ml 
 
Nil 
 
Nil 
 
   b)Total fungal   
      count 
Nil Nil Nil 
 
Table 13: PATHOGEN TESTING (STABILITY CONDITIONS) 
S.No Pathogens 
Accelerated condition 
(40±2°C / 75±5% RH)  
for 3  months 
Real time 
condition 
(25±2°C/60±5% 
RH)  for 3 months 
Refrigeration 
condition 
(5±3°C ) for 3 months 
1 
Escherichia 
coli 
Absent Absent Absent 
2 
Salmonella 
species 
Absent Absent Absent 
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INFERENCE 
The best formulation (S7) was kept in different storage conditions. During the 
storage period the product was checked for microbial contamination. For this formulation 
(S7) there was absence of pathogens, 10 bacterial colonies are formed in the accelerated 
conditions, but it was found to  be within the limits.82  And there was no countable fungal 
colonies observed in the both accelerated and real time conditions. 
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STABILITY TESTING 
Table 14: Stability Studies of formulated Roxithromycin Suspension 
(Formulation S-7) 
S.No 
Test for 
evaluation 
Accelerated condition 
(40±2°C / 75±5% RH ) for  
3  months 
Real time condition  (25 
±2°C/ 60±5% RH ) for  3  
months 
1 Taste No change No change 
2 Colour No change No change 
3 pH 3.74 3.67 
4 Viscosity (Cps) 660 665 
5 
Sedimentation 
volume (F) 
0.99 0.99 
6 
Drug  
content(%)* 
98.06±0.0236 98.97±0.0423 
*Mean ±SD (n=3) 
Table 15: Stability studies of formulated Roxithromycin Suspension under 
Refrigeration condition (Formulation S-7) 
S.No 
 
Test for evaluation 
Refrigeration condition 
 (5°C ± 3°C for  3months) 
1 Taste No change 
2 Colour No change 
3 Ph 3.74 
4 Viscosity (Cps) 660 
5 
Sedimentation 
volume(F) 
0.99 
6 Drug content (%) 98.06±0.0123 
7 Appearance 
Suspension is homogenous free 
from formation of crystals 
*Mean ±SD (n=3) 
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Table-16: In vitro drug release of Roxithromycin suspension 
Time  
(min) 
% DRUG RELEASED* 
Accelerated condition 
(40 ±2°C/ 75±5% RH ) 
for 3 months  
Real time condition  
 (25±2°C/ 60±5% RH ) 
for 3 months  
Refrigeration 
condition 
(5±3°C) for 3 months 
10 58.02±0.002 59.85±0.0231 57.25±0.0265 
20 70.56±0.0261 73.96±0.001 72.850±0.013 
30 88.91±0.0354 81.86±0.0365 82.35±0.0355 
60 97.08±0.0756 99.02±0.0023 98.65±0.0054 
*Mean ±SD (n=3) 
INFERENCE 
Stability studies of S-7 were carried out by placing the samples at different 
temperature and relative humidity (40 ±2°C/ 75±5% RH, 25±2°C/ 60±5% RH, 5±3°C) 
for 3 months in humidity chamber and evaluated. There is no significant change in 
release characteristics and other evaluation parameters. Based on the results it can be 
concluded that the formulated oral suspension was stable at room temperature over a 
period of 3 months. Even though stability is assured for 3 months, further studies at 
different temperature and humidity conditions are needed to establish its shelf life.  
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Fig.12: In vitro Release Profile for accelerated condition of optimized 
Roxithromycin Suspension 
 
 
 
 
Fig-13:In vitro Release Profile for Real Time Condition of Optimized S7 
Roxithromycin Suspension 
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Fig.14: In vitro Release Profile for Refrigerated Condition of Optimized S7 
Roxithromycin Suspension 
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SUMMARY AND CONCLUSION 
 
Several formulations were carried out by Drug-resin complexation method.  
 It was concluded that the formulation S-7 was satisfactory than other 
 formulations of S-1, S-2, S-3, S-4, S-5 & S-6. 
 The formulations S-7 was compared with a leading brand of marketed          
 sample and it was found to match with formulations S-7 in all aspects. 
 The bitter taste was masked in formulations S-7 better than the marketed 
 sample. 
 
FUTURE WORK  
 Scale up studies of the optimized formulation. 
 To send the desired formulated lots for Bioequivalence studies. 
 To proceed for exhibit batches. 
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